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The Medication Safety Program: Medication-Food
Risks and Behaviors Among the PACE Elderly
__________________________________________
Nutritional status and eating behaviors play a significant role in the clinical effects of
prescription drugs. Foods may alter the effect of drugs by interfering with
pharmacokinetic and pharmacodynamic mechanisms. In addition, the use of drugs
that interact with nutrients and affect eating behaviors are especially problematic for
the elderly, and, in addition to other health problems, frequently leads to
malnutrition. Despite the large clinical literature on the importance of specific drugfood interactions, little is known regarding these risks among the elderly. Magee
Rehabilitation Hospital has a long history of providing rehabilitation and primary
prevention programs for the elderly and is very interested in the potential role that
drug-food interactions may play in age related health problems including injury
secondary to falls.
In June of 1998 Magee Rehabilitation initiated the Medication Safety Program (MSP),
a three-phase research and demonstration project funded by SmithKline Beecham
Community Partnership. The goal of this research project was to explore the nature
and extent of risks, and the degree to which elderly are knowledgeable and
compliant regarding drug-food risks, in order to develop effective risk-reduction
interventions. In addition to Magee Rehabilitation and SmithKline Beecham, the MSP
partners included the Pennsylvania Department of Aging, the Pennsylvania
Department of Aging’s Pharmaceutical Assistance Contract for the Elderly (PACE)
Program, First Health Services Corporation, the Pennsylvania State University
(Departments of Biobehavioral Health and Nutrition), the Philadelphia Corporation for
Aging, MCP Hahnemann University, HealthGuard, HealthCentral and Sessa &
Associates.
Phase I of the MSP used historical data to examine the epidemiology of drug-food
interactions related to fluid and electrolyte balance in the PACE population. Several
databases containing pharmacy claims, drug attributes, and hospitalization records
were linked and analyzed retrospectively.
The first study, which examined the association between prescription drug use and
dehydration, found that 14% of all 1997 hospitalizations of PACE cardholders were
associated with a diagnosis of dehydration. Older age, male gender, nursing home
residence, and African-American race were all significantly and independently
associated with increased risk for dehydration. Dehydration risk increases by 11% to
36% with each additional potentially dehydrating drug that is taken.
The second study examined differences between blacks and whites for hospitalization
with hyperkalemia and hypokalemia. About 2% of hospitalized PACE enrollees were
diagnosed with hyperkalemia, and 6% were diagnosed with hypokalemia.
Hyperkalemia cases were more likely than controls to have used ACE inhibitors. In
this study, blacks experienced greater risk of hospitalization with hyperkalemia than
did whites, and this difference remained even when controlling for ACE inhibitor use.
However, there was no difference between groups in risk of hypokalemia.
Phase II of the MSP was comprised of two cross-sectional surveys—telephone and
mail—of PACE enrolled elderly. The surveys were targeted to specific risk groups of
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elderly who were determined to be at risk for specific adverse effects of drug-food
interactions. Risk groups included 1) elderly with diabetes; 2) warfarin users; 3)
antihypertensive users; 4) users of drugs with potential appetite-suppressant
effects; and 5) a random sample of PACE-enrolled elderly.
Of the 3,254 elderly who were contacted and identified as eligible for the study,
1,102 completed the telephone interview and of these, 81.7% subsequently
completed the mail survey. Results on risk indicators for 3 of the 5 risk groups
(elderly persons using antidiabetics, antihypertensives and anticoagulants)
unambiguously indicate that there is risk for significant adverse clinical consequences
due to lack of adequate knowledge of drug-food interactions and other health
promoting behaviors.
Less than 40% of individuals on anti-diabetic medications reported that they knew
certain foods could affect how well some medicines work. Only 1 out of 5 knew that
certain foods could cause problems with the particular medicines they were taking.
Among elderly antihypertensive users, only about 1 in 4 knew that certain foods
affect how well some medicines work. Survey results suggest that fewer than 1 in 4
users of anticoagulants are aware that dietary behaviors and some foods can cause
significant problems with the physiological effects of their anticoagulant medication.
Moreover, 3 out of 4 of this group report not receiving recommendations on eating
behaviors from any of their physicians or pharmacists. Finally, significant numbers of
elderly users of anticoagulants may be generally lax about medication safety with
about 12% reporting either taking fewer tablets than prescribed, taking their
medication less frequently, or else completely stopping taking a prescription.
Contrary to expectations, our findings suggest that PACE participants taking centrally
active medications with appetite suppressant properties may be at particular risk for
health problems associated with obesity, rather than appetite and weight loss. More
than 9 out of 10 elderly using drugs with appetite suppressant effects were not
advised about the possible effects of their medications on appetite.
Phase I and II of the Medication Safety Program (MSP) have already made a
significant impact on at least one large-scale health care system in Pennsylvania.
Based on the results of the first two phases of this research program, PACE has
agreed to include risk surveillance for drug-nutrition as part of their Retrospective
Drug Utilization Review and Prospective Drug Utilization Review systems. Still, the
full impact of the MSP program will not be realized until the completion of the
proposed Phase III Intervention Plan. Thus far, the MSP research findings from
Phase I and Phase II have mainly the potential to improve the health of the elderly
by justifying interventions and by raising the consciousness of health care planners
and providers. The true large-scale impact of the MSP program will be realized
through funding and implementation of the planned Phase III risk-reduction
programs.
For more information contact Lynn McGillin at 215-587-3180.
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